2 top growth stocks I’d consider buying right now

Today’s updates from these two exciting growth stocks show plenty of promise, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Biopharm stock Abzena (LSE: ABZA) is up after posting a 41% rise in underlying revenues in today’s full-year results. That’s a promising headline figure but the company’s share price is up only slightly, reflecting a business in transition that is still making a loss, yet with strong growth prospects as well.

The buzz about Abzena

This is the first time Fool UK has covered the £91.85m life sciences group and you have got off lightly, with the share trading 50% lower than two years ago. However, it is up a thrilling 25% in the last month, helped by May’s news that development partner True North Therapeutics Inc was acquired by Bioverativ Inc for $400m.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Today’s 2017 results show revenue increased 89% to £18.7m, up from £9.9m in 2016. However, a growing company like this also has plenty of expenses, notably the administrative cost of expanding in the US, and research and development expenditure. It reported a loss of £9.1m, down 6% on 2016’s £9.7m. Cash at year-end also fell sharply, from £13.7m to £4.1m.

Bought the biopharm

Chief executive John Burt describes the past 12 months as a combination of integration and preparing the group for significant growth. The business has a solid platform after raising £23.9m to fund investment and growth which will accelerate our progress towards profitability”.

City analysts predict another pre-tax loss of around £9.71m in 2018, with earnings per share down 41%, then a smaller loss of £3.87m in 2019. The direction of travel is good, but the road may be bumpy. You don’t need me to tell you that early stage biopharmaceutical stocks can be risky. However, Abzena could be worth a place on your watchlist.

First class at Oxford

Oxford Instruments (LSE: OXIG) is a commercial spin-off from the university and its results got top marks today, with the share price up more than 6% at time of writing. The smart science company, whose products include atomic force microscopy, microanalysis systems and, er, nanomanipulation thingies, is up 50% in the past 12 months, so momentum is building nicely.

Today’s preliminaries reveal a 9.1% rise in revenues to £348.5m, although down 3.7% at constant currency. Adjusted profit before tax rose 7.1%, in line with company expectations. Net debt reduced from £128.2m in 2016 to £109.3m, with leverage falling from 2.3 to 2.1 times thanks to good cash conversion and the sale of Oxford Superconducting Technology. The full-year dividend was maintained at 13p, offering a yield of 1.3%. This £620m company is clearly a growth rather than income play and boasts a stronger order book, up 9.3% over the year.

Musical instruments

Like Abzena, Oxford Instruments is also a company in transition. Chief executive Ian Barkshire said it had delivered a stable performance and remained positive despite uncertain academic and R&D funding levels. “Fundamental improvements to our structure, operations and strategy are under way and give us a solid platform to return to sustainable growth, at improved margins over the medium term.” 

City forecasters are positive, with 2017’s pre-tax loss of £25.5m forecast to turn into a £40.98m profit in 2018 and £42.52 in 2019. A valuation of 20.73 times earnings may reflect an exciting growth prospect.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Social media and digital online concept, woman using smartphone
Investing Articles

Will Lloyds shares recover in 2022?

Lloyds shares have struggled this year and the looming recession won't help. But I'd still buy them today.

Read more »

Two hands holding champagne glasses toasting each other with Paris in the background
Investing Articles

Can the stock market make me rich even now?

Here are three ways I'm coping with the stock market's recent bout of weakness and aiming to build wealth in…

Read more »

Cogs turning against each other
Investing Articles

3 top investment trusts to buy right now

Investment trusts offer a wide range of options for investors. And in troubled times, they provide some safety through diversification…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Why hasn’t the FTSE 100 crashed in 2022?

The catastrophic events of 2022 have left investors around the globe fearing the worst for stock markets. And some have…

Read more »

Trader on video call from his home office
Investing Articles

2 inflation-resistant FTSE 100 stocks to buy today

Soaring inflation could dent my returns if I don't take care. Here are two top inflation-resistant FTSE 100 stocks I'd…

Read more »

Tabletop model of a bear sat on desk in front of monitors showing stock charts
Investing Articles

Why a bear market is an investor’s best friend

A bear market can certainly be scary. But any investor tempted to sell might benefit by looking at Warren Buffett's…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

The Rolls-Royce share price could be stuck below £1 for a while. Should I buy?

The Rolls-Royce share price has been trading at penny stock levels since April. Could the stock be a bargain at…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

I’m aiming to make £45,000 in passive income with UK shares and never work again!

Investing regularly in UK shares can generate a substantial passive income over the long run. Zaven Boyrazian demonstrates how.

Read more »